usp795 non-sterile compounding compliance guide

SOSCLEANROOM | NONSTERILE COMPOUNDING COMPLIANCE RESOURCE

Make USP <795> Readiness Visible, Measurable and Repeatable.

A practical self-assessment and evidence guide for nonsterile compounding: personnel competency, cleaning schedules, ingredient traceability, formulation records, beyond-use dating, quality oversight and inspection preparation.

Open Expanded Checklist ↓ Original 2-Page PDF →

Start with applicability

Understand when USP <795> governs the preparation.

USP General Chapter <795> provides minimum standards for compounded nonsterile preparations (CNSPs) for humans and animals. It is not an ISO cleanroom-classification standard. The revised chapter became official on November 1, 2023; legal applicability and inspection expectations depend on the governing jurisdiction and the current official USP–NF text.

Situation	Relevant framework	Decision point
Customized nonsterile oral liquid, capsule or topical preparation	USP <795> and applicable pharmacy laws	Identify the actual compounding operation, formulation and responsible person.
Sterile compounded preparation	USP <797> and other applicable requirements	Do not use nonsterile compounding controls to replace aseptic controls.
Hazardous-drug compounding or handling	USP <800> plus the applicable compounding chapter	Review exposure, containment, PPE and deactivation/decontamination separately.
Reconstitution performed exactly per approved manufacturer labeling	Not automatically <795> compounding	Distinguish labeled reconstitution from modification beyond labeling; verify other rules.
Commercial drug manufacturing	FDA cGMP and applicable manufacturing regulations	Pharmacy compounding guidance is not a substitute for drug manufacturing compliance.

Primary authority: USP official chapter portal and USP–NF chapter record. Check the currently applicable revision before approving facility procedures.

Why it matters

A checklist should connect every control to a patient-safety outcome.

Contamination

Prevent unintended ingredients and microorganisms

Manage ingredient carryover, allergens, personnel transfer, dirty equipment and unsuitable cleaning practices.

Strength and uniformity

Prevent dosing variability

Use approved formulation methods, appropriate weighing and mixing equipment, and documented in-process checks.

Identity and labeling

Prevent selection or dispensing errors

Align ingredient identity, preparation strength, container labels, administration route and directions.

Stability and storage

Protect product quality over time

Assign defensible BUDs, use suitable containers and confirm storage and transport assumptions.

Traceability

Support investigation and recall

Connect a finished preparation to components, lot numbers, personnel, equipment and compounding records.

Oversight

Identify gaps before patient impact

Maintain training, documentation review, complaint handling, deviations and corrective actions.

Operating model

Build one quality system—not disconnected daily checklists.

01 | Governance

Name accountable people

Designate qualified oversight, authorize procedures, define escalation routes and document review responsibilities.

02 | Qualification

Train and observe performance

Qualify staff initially and at least every 12 months where specified, with retraining after deficiencies.

03 | Facility controls

Control the environment and equipment

Maintain a designated compounding space, hygiene, safe component storage and appropriate equipment.

04 | Standard execution

Control the formulation and cleaning work

Use current MFRs, complete Compounding Records, approved cleaning agents and documented practices.

05 | Quality verification

Check before release

Record required inspections, labels, BUD basis, deviations and quality decisions.

06 | Feedback loop

Investigate and improve

Trend problems, close CAPA, review SOPs and requalify people or processes as needed.

These are operational groupings created for this guide. They are not numbered sections of USP <795>. Specific “must” requirements should be verified against the chapter and the jurisdiction that applies to your facility.

Personnel qualification

Competency means demonstrated ability—not merely a signed attendance sheet.

ASHP’s 2023 comparison of the revised chapter identifies initial qualification and reevaluation at least every 12 months for personnel performing or directly overseeing compounding. Personnel should demonstrate the practices they actually perform, including hygiene, calculation, measuring, mixing, cleaning, documentation and response to deviations.

Competency area	What to observe	Useful evidence
Hand hygiene and gloves	Correct hygiene before compounding, glove condition and change triggers	Observation record, trained-person roster, competency sign-off
Component handling	Checking identity, grade, expiration and lot; avoiding mix-ups	Practical demonstration, receiving and inventory SOP
Weighing and measuring	Equipment selection, zeroing, measurements and calculations	Competency worksheet, equipment verification log
Formulation technique	Sequence, mixing, in-process check and container selection	Observed trial, MFR revision and training record
Cleaning and cross-contact prevention	Appropriate agents, order of steps and re-use controls	Cleaning SOP, observation record, completed log
Documentation and release	Complete CR, identify mistakes, communicate deviations	Reviewed simulated record, quality disposition

Gloves are required during compounding under the 2023 chapter. Additional garb depends on the activity and risk; it is not automatically identical to sterile gowning. Special protection applies where hazardous chemicals or drugs are handled.

Facility readiness

A designated, maintained compounding area is not necessarily an ISO-classified cleanroom.

Space: Identify a dedicated compounding area by the facility’s documented method; minimize simultaneous incompatible activities, clutter, and cross-contact.
Surfaces: Use cleanable surfaces and equipment that withstand the approved cleaning and sanitizing agents.
Storage: Store components and finished CNSPs under their specified conditions; document temperature monitoring and respond to excursions.
Equipment: Verify accuracy per manufacturer instructions or the applicable chapter requirement, whichever controls; keep service and maintenance histories.
Powders: Document an assessment of whether operations that produce airborne chemical particles require a closed-system processing device; treat hazardous-drug containment separately.
Preparation flow: Plan receiving, weighing, mixing, packaging, labeling and waste removal to minimize errors and contamination.

Where containment ventilated enclosures are used, check their required certification schedule and performance records. A suitable enclosure alone does not address hazardous-drug handling requirements under USP <800>.

Cleaning and sanitizing

Define location, frequency, chemistry, technique, and proof of completion.

Cleaning physically removes soil and residues; sanitizing reduces microbial contamination under the selected agent’s labeled conditions. When separate products or steps are required, cleaning comes before sanitizing. 70% isopropyl alcohol is not a universal replacement for all required cleaning or sanitizing actions, and chemical suitability must be assessed for the surface and material.

Location	Practical scheduling benchmark from revised-chapter guidance	What to document
Compounding work surfaces	Beginning and end of each shift on compounding days; between CNSPs with different components; after spills or suspected contamination	Date/shift, person, agent and exceptions
Floors	Daily on compounding days; after spills or known/suspected contamination	Daily cleaning record and corrective action
Walls and ceilings	When visibly soiled or contamination is known/suspected; verify current official chapter before locking SOP frequency	Inspection and event-triggered cleaning
Storage shelving	At least every 3 months, and when spills or contamination occur	Periodic schedule and completion record
Processing equipment / enclosures	Per approved equipment-specific procedures; between applicable preparations and after contamination events	Equipment ID, process, log and release to use

Revision caution: The older 2019-postponed text gave walls a quarterly interval; do not copy that obsolete interval into a 2023-based checklist without confirming the operative official text. ASHP’s USP 795 Key Changes and the USP 2023 commentary help explain the revision.

The five elements of a defensible cleaning SOP

Agent

Specify approved cleaner / sanitizer

Record exact product and concentration, preparation, labeling, shelf life, compatibility and applicable wet contact time.

Applicator

Choose the right tool

Wiper, mop or swab should suit the surface, agent and shedding tolerance; document any sterile/nonsterile requirements.

Method

Describe the actual technique

Include direction of wiping, wipe-face rotation, solution handling, correct sequence and disposal.

Trigger

Define when to repeat

After changeover, spills, visibly soiled surfaces, unknown contamination or missed schedules as applicable.

Record

Make completion provable

Use location-specific logs, exception handling and defined owner review.

Ingredients and equipment

Start traceability at receipt and preserve it through the final record.

Component acceptance should evaluate source, identity, grade, lot, expiration, package integrity, certificate of analysis where required, and storage conditions. The chapter introduced tighter expectations for API sourcing and certificates of analysis; evaluate each ingredient under the operative requirements and appropriate pharmacy oversight.

Checkpoint	Operational question	Evidence
Receiving	Was the correct material received in acceptable condition?	Supplier, receipt date, lot, quantity, expiry, acceptance / rejection record
Storage	Were temperature and handling requirements maintained?	Location and monitoring logs; excursion review
Dispensing	Was the correct lot and calculated quantity selected?	Component labels, weighing/measuring and CR entries
Tools and equipment	Is the equipment appropriate and verified?	Equipment ID, calibration/verification and cleaning record
Changeover	Could carryover occur between compounds?	Cleaning log, dedicated-tool controls, line clearance
Release	Can every finished preparation be traced?	MFR + CR + label + review signoff

Formulation records

MFRs establish the method; Compounding Records prove what happened.

Master Formulation Record (MFR)	Compounding Record (CR)
Approved formula identity, strength and dosage form	Specific preparation date and unique identification
Ingredients and quantities; required equipment and supplies	Actual ingredient sources, quantities and lot numbers
Standardized sequence, mixing method and in-process checks	Personnel, actual process and critical checks completed
Container-closure, packaging and quality requirements	Final yield, observations and QC/release decisions
Assigned BUD rationale, storage, specific labeling content	Assigned BUD, final label and reviewer documentation

An MFR should exist for each unique formulation and a CR for every CNSP. The facility must control revisions and ensure that actual deviations are visible rather than corrected silently. Consult the official USP chapter for the exact set of required data elements and exceptions.

Beyond-use dates

A BUD is an evidence-based limit, not the expiration date of the original ingredient.

When no applicable USP–NF compounded preparation monograph or CNSP-specific stability data establishes a more appropriate limit, the revised framework uses the preparation type and water activity (a_w). The figures below are summarized limits, not automatic permitted dates. Product-specific chemical/physical stability, container compatibility and other considerations can require a shorter BUD.

Preparation category	Illustrative upper BUD limit without stronger specific evidence	Storage context
Nonpreserved aqueous (a_w ≥ 0.60)	14 days	Refrigerated
Preserved aqueous (a_w ≥ 0.60)	35 days	Controlled room temperature or refrigerated
Nonaqueous oral liquid (a_w < 0.60)	90 days	Controlled room temperature or refrigerated
Other nonaqueous dosage forms (a_w < 0.60)	180 days	Controlled room temperature or refrigerated

The category and BUD must be supported, not guessed from appearance alone. Check water activity, stability literature, dosage form, preservative considerations and manufacturer component expirations. For methodology see ASHP pharmacist BUD guide and ASHP summary of 2023 changes.

Example 01

Nonpreserved aqueous oral liquid

Where no stronger formulation-specific stability evidence exists, use the applicable refrigerated limit, but assign a shorter BUD if the formulation or components require it.

Example 02

Nonaqueous capsule

A preparation that is genuinely nonaqueous may fall into a longer-limit category, but actual stability, ingredient shelf life, packaging and applicable monographs remain decisive.

Warning

Do not classify from ingredients alone

“Contains water” is not the same as measured or adequately established water activity. Consult authoritative formulation references and approved pharmacy policy.

Final verification

Document the final check before the preparation leaves the controlled workflow.

Visual examination: Evaluate the final CNSP for expected appearance and physical characteristics before release; unexpected separation, particles or changes require review.
Strength and identity: Compare the intended formula, calculations and documented process with the actual preparation and final label.
Label: Verify name, strength/concentration, route, amount, BUD, storage conditions, instructions and any required warnings.
Packaging: Use a container-closure system appropriate for the preparation and protect it during transport.
Disposition: Hold any preparation with unresolved documentation, labeling, equipment or quality problems for authorized review.

Expanded practical audit tool

Use this evidence-based checklist to find missing controls—not to declare regulatory compliance.

Mark each square only after examining current evidence. Record a gap owner, corrective action and due date in your internal system. The original two-page PDF is retained below as a quick reference, but it does not contain every expanded check on this page.

Printable original checklist (January 2026)

The existing two-page SOSCleanroom PDF is preserved as a shorter historical quick-check. Use the expanded list on this page for a broader internal review; neither substitutes for the official chapter.

Open Original PDF →

A. Governance and quality assurance

Owner and policy controls to inspect at the start of a review.

Designated person(s) have documented authority and responsibility.

Evidence to inspect: Current designation in the SOP and a role description.

SOPs are current, approved and controlled.

Evidence to inspect: Revision list, signed approvals, archived versions.

SOPs are reviewed on the required cadence.

Evidence to inspect: Review dates, revised procedures and training acknowledgment.

Quality assurance and quality control responsibilities are assigned.

Evidence to inspect: QA/QC policy, approval roles and audit cadence.

Deviations, complaints, and adverse events have defined evaluation pathways.

Evidence to inspect: Sample incident report, investigation and disposition records.

Corrective actions are tracked to effectiveness review.

Evidence to inspect: CAPA register, due dates and verification of effectiveness.

B. Personnel, hygiene and garbing

Directly observed personnel should match qualification and SOP records.

Compounding and oversight personnel are initially trained and qualified.

Evidence to inspect: Training matrix and role-specific demonstration records.

Annual competency evaluation is current where required.

Evidence to inspect: Dates, assessments, follow-up for unsuccessful evaluations.

Hand hygiene practices are observed and appropriate.

Evidence to inspect: Procedure, observation, access to supplies.

Gloves are used for compounding and changed appropriately.

Evidence to inspect: Training, activity observation and approved glove selection.

Additional protective garb and reusable equipment follow documented procedures.

Evidence to inspect: Garb policy, cleaning/reuse guidance, PPE assessment.

Personnel report conditions that could increase contamination risk.

Evidence to inspect: Notification procedure and documented supervisory assessment.

C. Facilities and storage

Check the physical space alongside the facility maps and logs.

Designated nonsterile compounding area is identifiable and suitable.

Evidence to inspect: Area boundaries, use policy and physical inspection.

Surfaces are intact, cleanable and appropriate for selected agents.

Evidence to inspect: Condition inspection and cleaning compatibility review.

Components and preparations are stored under appropriate conditions.

Evidence to inspect: Storage map, labels and environmental records.

Storage temperatures and excursions are documented and assessed.

Evidence to inspect: Temperature log and completed excursion decisions.

Powder-generating tasks have a documented exposure/containment assessment.

Evidence to inspect: Risk assessment, enclosure choice and operator safeguards.

D. Equipment and components

Follow one recent lot from receipt through compounding.

Equipment is appropriate for the compounding activity.

Evidence to inspect: Inventory, equipment qualification or evaluation.

Equipment verification/calibration is current where required.

Evidence to inspect: Verification data and maintenance schedule.

Containment equipment meets applicable certification requirements.

Evidence to inspect: Current certification and service reports, if used.

Incoming components are received and accepted by written procedures.

Evidence to inspect: Supplier, quantity, receipt date and identification.

Required API sourcing and certificates are verified.

Evidence to inspect: Manufacturer/registration evidence and CoA as applicable.

Lot numbers, expirations and storage conditions remain traceable.

Evidence to inspect: Receipt-to-CR cross-check, inventory controls.

Nonhazardous spill and waste procedures are documented.

Evidence to inspect: SOP, training and incident records.

E. Cleaning and sanitizing

Observe technique and verify logs, not just the existence of products.

Cleaning and sanitizing agents are approved for the task and surfaces.

Evidence to inspect: Agent list, label/SDS, contact time and compatibility rationale.

Work surfaces receive required beginning/end-of-shift cleaning.

Evidence to inspect: Dated work-surface logs matched to compounding schedule.

Work surfaces are cleaned between preparations with different components.

Evidence to inspect: Turnover record, area observation, documented process.

Floors and storage shelving follow applicable frequencies.

Evidence to inspect: Daily/periodic schedules and log evidence.

Event-driven cleaning follows spills and contamination observations.

Evidence to inspect: Incident log and cleaning completion.

Equipment cleaning and sanitation are documented.

Evidence to inspect: Equipment-specific procedure and use/clean status.

Wipers, swabs and mops are appropriate and managed to prevent cross-contact.

Evidence to inspect: Approved supply list, disposal/change-out practice.

F. Formulation and compounding records

Select one released CNSP and perform a complete vertical trace.

A current MFR exists for every unique CNSP formulation.

Evidence to inspect: Approved master document, version and change records.

Each compounded CNSP has a complete Compounding Record.

Evidence to inspect: Dated CR including personnel, component lot and quantity.

Actual steps, calculations and checks are traceable.

Evidence to inspect: Weighing/measuring notes, in-process results.

Changes or deviations are authorized and documented.

Evidence to inspect: Deviation review and impact assessment.

Final release inspection and record review are complete.

Evidence to inspect: Finished product check and authorized disposition.

G. BUD, label and distribution

Compare one actual filled container with its source record.

BUD category and rationale are documented.

Evidence to inspect: Monograph/stability citation, water activity basis, decision.

Shorter stability limits are honored when necessary.

Evidence to inspect: Ingredient expiry, container or published stability constraint.

Final label matches the CR and required clinical directions.

Evidence to inspect: Label-to-record comparison and final check.

Package and storage conditions support the assigned BUD.

Evidence to inspect: Container specification and handling instructions.

Transport and excursion processes are defined.

Evidence to inspect: Delivery procedure and event disposition.

H. Follow-up and continuous readiness

Conclude with a tracked action register rather than a blanket pass/fail claim.

Gaps are prioritized according to potential patient harm.

Evidence to inspect: Risk-ranked findings and interim controls.

Every finding has an accountable owner and due date.

Evidence to inspect: Action register and management review.

Effectiveness of completed actions is rechecked.

Evidence to inspect: Follow-up observation, record sample or training evaluation.

Site-specific state and federal requirements are reviewed.

Evidence to inspect: Applicable jurisdictional standard and regulatory notes.

Inspection walk-through

A seven-step vertical trace provides a practical reality check.

01 | Select

Choose a recent preparation

Pick a representative high-volume or higher-risk CNSP and identify the applicable formulation and finished label.

02 | Confirm method

Retrieve the approved MFR

Check version, process, ingredients, QC and BUD references.

03 | Verify actual work

Open the matching CR

Trace personnel, calculations, measurements, lots and actual execution.

04 | Check the environment

Compare dates and logs

Match compounding date to equipment, cleaning, training and storage records.

05 | Confirm final product

Examine packaging and label

Compare strength, route, storage, BUD, quantity and review sign-off.

06 | Investigate anomalies

Document the difference

Determine affected preparations, patient risk, containment and disposition.

07 | Close

Track corrective action

Assign ownership and verify that changes actually improved control.

This is a suggested self-audit technique; it does not imply every regulator uses the same inspection sequence. Maintain records securely and do not place patient-identifying information in public forms or vendor communications.

Frequent failure modes

Look for evidence gaps before they create clinical risk.

Observed finding	Why it matters	Useful corrective direction
No annual training demonstration	Personnel may perform uncontrolled methods	Schedule observed competencies; assess affected production and retrain.
Cleaning log present but different from actual work	Records may not demonstrate cleaning was performed	Reconcile timestamps, areas, agents, personnel and SOP requirements.
Master formula exists but lot numbers absent from CR	Finished CNSP cannot be traced to incoming components	Correct process design; investigate records and potential product impact.
BUD copied from a prior formulation	Different water activity or stability assumptions may apply	Reassess formulation-specific evidence, approved BUD and released stock.
Glove or disinfectant substituted informally	Barrier or chemical performance may change	Hold unauthorized substitutions for qualified review and SOP update.
Powder work performed without documented assessment	Potential worker exposure or cross-contamination	Perform and approve task-specific exposure/containment review.
Final visual check not recorded	Release verification is incomplete	Review release procedure, affected preparations and correction.

Tools that support repeatability

Source supplies to a defined SOP—not the other way around.

USP does not certify or endorse SOScleanroom products. The products below are examples of catalog items that may support an approved nonsterile compounding workflow after customer assessment. Their use alone cannot establish USP compliance.

Nonsterile polyester wiper

Texwipe TX1009 AlphaWipe 9 × 9

For compatible work-surface cleaning and solution application; verify wetting agent, residue requirements and wipe change-out.

Detail-cleaning swab

Texwipe TX714A Large Alpha Swab

Nonsterile polyester swab for accessible features and equipment detail cleaning when an approved method specifies it.

Nonsterile nitrile glove

Ansell 93-311 Nitrilite

A cleanroom glove option; evaluate actual glove sizing, chemical exposure, barrier compatibility and site garbing requirements.

Chemical selection

Browse Nonsterile 70% IPA

Choose cleaning and sanitizing agents by their label claims, surface compatibility, safety instructions and SOP.

Compounding support

Browse Swabs

Assess tip type, materials, shedding, package configuration and compatible liquid application.

Repeat purchasing

Special Cleanroom Consumable Pricing

Standardize approved part numbers and packaging with replenishment arrangements; substitutions remain customer-controlled.

For adjacent education consult USP 795 detailed introduction, USP 797 sterile compounding guide, USP 800 hazardous drug guide, Glove Sizing Guide and Technical Vault.

Frequently asked questions

Short answers to common nonsterile-compounding readiness questions.

Does USP <795> require an ISO Class 5 cleanroom?

No universal ISO Class 5 requirement follows from nonsterile compounding under <795>. The facility must still provide a suitable designated compounding space and controls consistent with the operation and applicable requirements.

When did the revised chapter become official?

The revised USP <795> became official November 1, 2023. Determine how the currently official text is adopted and enforced by the relevant jurisdiction.

Does the two-page SOS checklist certify compliance?

No. It is a dated educational quick-reference, and the longer on-page assessment is also an educational tool. Only the appropriate authority can determine compliance in its jurisdiction.

How often should personnel competency be evaluated?

The revised chapter includes initial training and evaluation at least every 12 months for people who compound or directly oversee compounding. Additional triggers and role-specific training may apply.

Are gloves required?

The revised USP <795> requires gloves during compounding. Choose and change them appropriately for the process, chemicals and risk; sterile gloves are not universally required for all nonsterile compounding.

Must every product have a Master Formulation Record?

The revised chapter requires an MFR for each unique formulation and a Compounding Record for each compounded preparation, subject to the actual chapter language and applicable circumstances.

Is 70% IPA enough for all nonsterile cleaning?

No. A suitable cleaning/sanitizing program must address residues, antimicrobial needs, manufacturer label contact time, surface compatibility and procedure-defined sequencing.

Do all areas need to be cleaned every day?

No single daily frequency applies to every surface. Work surfaces and floors have compounding-day schedules; shelving and walls/ceilings have different periodic or event-driven triggers. Verify the operative chapter text.

Does a sterile wiper make the compounded preparation sterile?

No. A sterile consumable alone neither sterilizes the preparation nor converts nonsterile compounding into sterile compounding.

How are BUDs chosen?

Use any applicable USP–NF compounded preparation monograph and qualified formulation-specific stability evidence, then the revised category and water activity framework when applicable. Shorter dates may be required.

Are a manufacturer expiration date and a BUD interchangeable?

No. The manufacturer expiration date applies to the commercial component or product, whereas the CNSP BUD reflects the compounded preparation and its supported storage conditions.

Does handling hazardous drugs fall under USP <795> alone?

No. Relevant hazardous-drug controls under USP <800> must be assessed in addition to the applicable compounding chapter and laws.

What is the fastest meaningful internal audit?

Choose a released CNSP and trace the MFR, CR, ingredients, equipment, cleaning, staff qualifications, BUD rationale, label and final review as one chain.

What if a required record is missing?

Document the gap, evaluate potential effects on the affected CNSPs, use authorized quality disposition, and address root causes. A retrospective reconstruction should never be presented as an original contemporaneous record.

Primary references

Use official publishers and professional implementation tools.

The authoritative requirements are the operative official USP–NF text and applicable law—not SOSCleanroom commentary, a past USP draft, or an informal internet checklist. Full chapter access may require USP credentials. The selected references below document the context used to prepare this guide.

Reference	Why consult it
USP General Chapter 795 portal	Current chapter pathway, updates, FAQs and implementation information.
USP–NF chapter record	Chapter scope and official chapter access pathway.
ASHP: USP 795 Key Changes (2023)	Summary of revisions to personnel, facilities, records, cleaning, equipment and BUD concepts.
ASHP: List of Standard Operating Procedures	Checklist of SOP domains from the revised chapter; use with full official text.
USP 2023 chapter commentary	Explanations of the revision process and cleaning/documentation changes.
ASHP: The Pharmacist Guide to Assigning a BUD	Professional guidance on BUD definitions, stability and compounding decisions.
Original SOSCleanroom 2026 quick-check PDF	Retained historical printable resource; shorter than the expanded checklist on this page.

SOSCLEANROOM | NONSTERILE COMPOUNDING SUPPLY SUPPORT

Standardize Supplies. Strengthen Your Execution.

Need approved wipers, gloves, swabs, cleaners, mops or repeat purchasing support? Share your part numbers, required packaging, annual usage and documentation needs. Our team can assist with sourcing and product comparisons; your pharmacy retains responsibility for approving supplies, validating methods and satisfying applicable compounding requirements.

Request a Quote →Explore the Technical Vault →

Questions? 800-443-7101 | sales@sossupply.com

Educational and legal scope: Technical source review October 27, 2026. This is an independent educational planning resource and not a verbatim reproduction of USP text, a substitute for a licensed USP–NF chapter, a patient-specific clinical protocol, a legal opinion, a regulatory audit, or a certification of compliance. The facility’s qualified personnel and applicable authorities determine requirements, SOPs, quality decisions, product qualification and enforcement. The January 2026 two-page SOS quick-check PDF is retained as a distinct, shorter resource and has not been replaced by the online expanded assessment. Verify current standards, product documentation and jurisdictional requirements before use.